Eversheds Sutherland advises Azurity Pharmaceuticals on Acquisition of Sebela’s Bowel Prep Franchise | Client News

4335978 - pipette with drop of liquid over test tubes for an experiment in a science research lab4335978 - pipette with drop of liquid over test tubes for an experiment in a science research lab

Eversheds Sutherland advises Azurity Pharmaceuticals on Acquisition of Sebela’s Bowel Prep Franchise

November 24, 2025

United States
United States
United States
Eversheds Sutherland is pleased to have advised Azurity Pharmaceuticals on its acquisition of Sebela’s Bowel Prep Franchise, including two leading bowel preparation therapies for colonoscopies.

The strategic transaction further strengthens Azurity’s commitment to serving overlooked patients by advancing access to medicines. By integrating Sebela’s bowel prep franchise, Azurity will expand its product offerings and capabilities to healthcare providers and patients in the United States.

With the acquisition, Azurity welcomes more than 50 colleagues from Sebela’s commercial and support teams.

Read Azurity’s press release here.

The Eversheds Sutherland team was led by Partner Mike Voynich (Corporate), with support from Partner Pete Pappas (Intellectual Property), Special Counsel Anna Halsey (Intellectual Property), Senior Associate Adam Byrne (Corporate) and Associate Haley Klass (Corporate).

The materials on the Eversheds Sutherland website are for general information purposes only and do not constitute legal advice. While reasonable care is taken to ensure accuracy, the materials may not reflect the most current legal developments. Eversheds Sutherland disclaims liability for actions taken based on the materials. Always consult a qualified lawyer for specific legal matters. To view the full disclaimer, see our Terms and Conditions or Disclaimer section in the footer.

Services

Industries

Key contacts

michaelvoynich@eversheds-sutherland.com

Michael J. Voynich

Partner

Atlanta, United States

Latest Insights

Latest News

Latest Events

shopping district

legal updates

May 29, 2026

Consumer Lens - Session 1 | The Rise of European Class Actions

Business meeting close up discussing data

podcasts and webcasts

May 29, 2026

Tax NOLs in Cross-Border Structures Webinar

Pay-Transparency-Waterdroplets-on-glass

legal updates

May 28, 2026

EU Pay Transparency Directive

Financial district skyscrapers glass high-rise buildings urban skyline

legal updates

May 27, 2026

Trade secrets and the Digital Omnibus: key risks and safeguards

© Eversheds Sutherland 2026. All rights reserved. Eversheds Sutherland is a provider of legal and other services operating through various separate and distinct legal entities. For further information about these entities and Eversheds Sutherlands' structure please see the Legal Notice page of this website.

Eversheds Sutherland is the name and brand under which the members of Eversheds Sutherland Limited (Eversheds Sutherland (International) LLP and Eversheds Sutherland (US) LLP) and their respective controlled, managed or affiliated firms and the members of Eversheds Sutherland (Europe) Limited and Eversheds Sutherland (Africa) Limited (each an "Eversheds Sutherland Entity" and together the "Eversheds Sutherland Entities") provide legal or other services to clients around the world. Eversheds Sutherland Entities are constituted and regulated in accordance with relevant local regulatory and legal requirements. The use of the name Eversheds Sutherland, is for description purposes only and does not imply that the Eversheds Sutherland Entities are in a partnership or are part of a global entity. The responsibility for the provision of services to the client is defined in the terms of engagement between the instructed firm and the client. For further information about these Eversheds Sutherland Entities and Eversheds Sutherlands’ structure please see the Legal Notices page of this website. For information on Konexo please also see the Legal Notices page of this